Browsing: Metabolism

In a 16-week randomized study of women with obesity and PCOS, semaglutide improved taste recognition by an estimated 2.5 points versus placebo.

In a J Clin Endocrinol Metab randomized trial, All patterns of light-intensity walking reduced postprandial glucose concentrations and diastolic BP in young obese adults, suggesting benefits for glycemic control. Key reported results included Compared with SIT, all walking conditions reduced iAUCs…

In a J Clin Endocrinol Metab randomized trial, In older men with obesity and hypogonadism, adding TRT for 6 months to LT does not result in further improved cardiometabolic profiles and could potentially blunt some of the metabolic benefits induced by LT. Key reported results included HbA1c…

Adding topiramate to metformin improved 6-month weight loss in women with PCOS, but the benefit was modest and paresthesia was more common.

ATTAIN-1 found that oral orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks in adults with obesity without diabetes.

In STEP UP, semaglutide 7.2 mg reduced body weight by 18.7% versus 3.9% with placebo and outperformed semaglutide 2.4 mg in adults with obesity without diabetes.

In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.

In REDEFINE 1, once-weekly cagrilintide-semaglutide produced 20.4% mean weight loss at 68 weeks versus 3.0% with placebo in adults with overweight or obesity without diabetes.

In REDEFINE 2, CagriSema reduced weight by 13.7% versus 3.4% with placebo at 68 weeks, and 73.5% achieved HbA1c <=6.5% in adults with type 2 diabetes.

A single-centre Egyptian RCT found the Diabetes Conversation Map programme improved diabetes knowledge, self-management, and self-efficacy questionnaire scores versus standard education (p < 0.001), with no clinical endpoints reported. PICO summary and expert commentary.